Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

Benzinga · 1d ago
Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.